Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit
19. Oktober 2021 07:00 ET
|
Retrotope
Data Demonstrate RT011 Offers Dose-Dependent Protection Against Retinal Lipid Peroxidation (LPO) and Cell Damage, as well as Preservation of Visual Function Findings Provide Rationale for Advancement...
Retrotope Reports Data from Phase 2/3 Clinical Trial of RT001 and Concurrent Natural History Study in Patients with Infantile Neuroaxonal Dystrophy (INAD)
06. Oktober 2021 07:00 ET
|
Retrotope
Treatment with RT001 Results in Statistically Significant Improvements in Overall Survival and Progression Free Survival for INAD Patients as Compared to Control Benefits Supported by Totality of...
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Progressive Supranuclear Palsy (PSP)
11. August 2021 07:00 ET
|
Retrotope
LOS ALTOS, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
21. April 2021 07:00 ET
|
Retrotope
LOS ALTOS, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
17. März 2021 07:00 ET
|
Retrotope
LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Retrotope to Present at H.C. Wainwright Global Life Sciences Conference
03. März 2021 16:05 ET
|
Retrotope
LOS ALTOS, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications
25. Februar 2021 07:00 ET
|
Retrotope
Company Currently Conducting Late-Stage Clinical Trials in Both Infantile Neuroaxonal Dystrophy (INAD) and Friedreich’s Ataxia (FA) RT001 also Granted Fast Track Designation by FDA in FA; Orphan Drug...
Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)
09. Januar 2020 10:24 ET
|
Retrotope
LOS ALTOS, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that it has dosed its first patient in a Phase 2/3 clinical trial of RT001 in Friedreich’s ataxia, the most common of...
Retrotope Announces Full Enrollment of Phase 2/3 trial in patients with Infantile Neuroaxonal Dystrophy (INAD)
07. August 2019 10:00 ET
|
Retrotope
LOS ALTOS, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today that it has fully enrolled all patients in the first clinical trial of a possible treatment for infants with the...
Retrotope Announces RT001 Clinical Data Presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting
06. Mai 2019 12:57 ET
|
Retrotope
LOS ALTOS, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Retrotope announced today positive findings from an expanded access study of the company’s lead candidate, RT001, in a patient with LOTS, as...